Summary
The dose-dependent inhibition of platelet aggregation by the chemically stable, prostacyclin-mimetic, iloprost, was studied in patients suffering from stage II–III peripheral arterial obliterative disease (PAOD). The study was designed as a randomized placebo-controlled cross-over trial. Iloprost was administered i.v. to six patients at doses of 0.5, 1.0, 2.0 or 3.0 ng/kg×min for 4 h, with an interval of 2–3 days between the infusions. During iloprost infusion, systolic and diastolic arterial blood pressure, heart rate and blood flow in the affected limb remained unchanged. In contrast, there was a considerable, dose-dependent inhibition of ADP- and thrombin-induced platelet aggregation and secretion ex vivo at doses of 0.5–2.0 ng/kg×min iloprost, indicating that iloprost reduced platelet stimulation by 50%–70%. The antiplatelet action of iloprost remained unchanged during infusion but ceased with 2 h after administration had ended. The agent was tolerated by the patients without unacceptable side-effects at doses up to 2 ng/kg × min. It is concluded that iloprost administered i.v. at doses of 1–2 ng/kg×min in patients with stage II–III PAOD does not involve haemodynamic side-effects and might be considered an effective antiplatelet agent.
Similar content being viewed by others
Abbreviations
- ADP:
-
Adenosinediphosphate
- PGI2 :
-
Prostacyclin
- PRP:
-
platelet rich plasma
- TXA2 :
-
Thromboxane A2
- 12-HPETE:
-
12-hydroperoxy-eicosatetraenoic acid
References
Belch JJF, Geer I, McLaren M, Saniabadi AR, Miller S, Sturrock RD, Forbes CD (1984) The effects of intravenous ZK 36374, a stable prostacyclin analogue, on normal volunteers. Prostaglandins 28:67–77
Bergman G, Kiff PS, Atkinson L, Kerkez S, Jewitt DE (1983) Dissociation of platelet aggregation and vasodilation with iloprost, a stable orally active prostacyclin derivative. Circulation [Suppl III] 68:398
Bugiardini R, Galvani M, Ferrini D, Gridelli C, Tollemeto D, Mari L, Puddu P, Lenzi S (1985) Myocardial ischemia produced by prostacyclin and iloprost. Clin Pharmacol Ther 38:101–108
Casals-Stenzel J, Haberey M, Loge O, Losert WF, Mannesmann G, Radüchel B, Schillinger E, Skuballa W, Town MH, Vorbrüggen H (1980) Pharmacology of a new potent and stable prostacyclin analogue, ZK 36374. Acta Ther [Suppl] 4:37
Chiesa R, Vicari A, Mari G, Galimberti M, Di Carlo V, Pozza G (1985) Use of stable prostacyclin analogue ZK 36374 to treat severe lower limb ischaemia. Lancet II:95–96
Cowley AJ, Heptinstall S, Hampton JR (1985) Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man. Thromb Haemostasis 53:90–94
Darius H (1985) Platelet and vascular effects of iloprost (ZK 36374) and its stereoisomere ZK 36375 — two chemically stable prostacyclin analogues. In: Schrör K (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 454–464
Darius H, Ahland B, Rücker W, Klaus W, Peskar BA, Schrör K (1984) The effects of molsidomine and its metabolite SIN-I on coronary vessel tone, platelet aggregation and eicosanoid formation in vitro — inhibition of 12-HPETE biosynthesis. J Cardiovasc Pharmacol 6:115–121
Data JL, Molony BA, Meinzinger MM, Gorman RR (1981) Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3′5′-cyclic monophosphate levels. Circulation 64:4–12
Hossman V, Heinen A, Auel H, FitzGerald GA (1981) A randomized, placebo-controlled trial of prostacyclin (PGI2) in peripheral arterial disease. Thromb Res 22:481–490
Hossmann V, Auel H, Rücker W, Schrör K (1984) Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease. a placebo-controlled cross-over study. Klin Wochenschr 62:1108–1114
Kaukinen S, Ylitalo P, Pessi T (1984) Hemodynamic effects of iloprost, a prostacyclin analog. Clin Pharmacol Ther 36:464–469
Keller J, Kaltenecker A, Schricker KT, Krais T, Schönberger A, Gevatter M, Hornstein OP (1984) Behandlung des Raynaud-Phänomens bei Sklerodermiepatienten mit einem neuen stabilen Prostacyclin-Derivat. Dtsch Med Wochenschr 109:1433–1438
Schrör K (1985) Kardiovaskuläre Wirkungen von Prostaglandin E1 (PGE1) — Mechanismen und ihre mögliche klinische Bedeutung. In: Schrey A (ed) PGE1-Therapie der arteriellen Verschlußkrankheit. Wolf, München, S 15–32
Schrör K, Verheggen R (1986) Prostacyclins are only weak antagonists of coronary vasospasm induced by authentic thromboxane A2 and serotonin. J Cardiovasc Pharmacol (in press)
Schrör K, Ohlendorf R, Darius H (1981a) Beneficial effects of a new carbacyclin derivative, ZK 36374, in acute myocardial ischemia. J Pharmacol Exp Ther 219:243–249
Schrör K, Darius H, Matzky R, Ohlendorf R (1981b) The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36374) — equipotent to PGI2 in vitro. Naunyn-Schmiedeberg's Arch Pharmacol 316:252–256
Schrör K, Darius H, Rücker W, Krüger J (1982) Wirkung eines neuen Prostacyclin-Analogs (ZK 36374) auf ATP, cAMP und Thromboxansynthese von Humanthrombozyten. In: Van de Loo J, Asbeck B (eds) Hämostase, Thrombophilie und Arteriosklerose. Schattauer, Stuttgart, S 572–575
Skuballa W, Vorbrüggen H (1983) Synthesis of ciloprost (ZK 36374): A chemically stable and biologically potent prostacyclin analog. Adv Prostaglandin Thromboxane Leukotriene Res 11:299–305
Smith EF III, Gallenkämper W, Beckmann R, Thomsen T, Mannesmann G, Schrör K (1984) Early and late administration of a PGI2-analogue, ZK 36374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 18:163–173
Szczeklik A, Skawinski S, Gluszko P, Nizankowski R, Szczeklik J, Gryglewski RJ (1979) Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet I:1111–1114
Szczeklik A, Gryglewski RJ, Nizankowski R, Skawinski S, Gluszko P, Korbut R (1980) Prostacyclin therapy in peripheral arterial disease. Thromb Res 19:191–199
Telles GS, Campbell WB, Wood RFM, Collin J, Baird RN, Morris PJ (1984) Prostaglandin E1 in severe lower limb ischaemia: a double-blind controlled trial. Br J Surg 71:506–508
Vane JR (1985) Prostacyclin in the cardiovascular system in health and disease. In: Schrör K (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 7–28
Author information
Authors and Affiliations
Additional information
Presented in part as a preliminary report at the II. International Prostaglandin Symposium, Nürnberg-Fürth, 1984
Rights and permissions
About this article
Cite this article
Darius, H., Hossmann, V. & Schrör, K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. Klin Wochenschr 64, 545–551 (1986). https://doi.org/10.1007/BF01735317
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01735317